Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel oncolytic virus combined with anlotinib in advanced malignant solid tumors
ChiCTR2100043643Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Guangxi University of Chinese Medicine
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of anlotinib in bronchial carcinoma, hepatocellular carcinoma (HCC) and Non-hematologic malignancy (3 arms), sponsored by First Affiliated Hospital of Guangxi University of Chinese Medicine. Primary endpoints: Disease Control Rate and Safety. Started Dec 2020; status: recruiting.
02
Drugs
anlotinib
03
Conditions
bronchial carcinomahepatocellular carcinoma (HCC)Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2100043643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043643.